Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Human Papillomavirus Vaccination Counseling in Pediatric Training
Gnagi, Sharon H. , Gnagi, Forrest T., Schraff, Scott A. , Hinni, Michael L.

Otolaryngology–Head and Neck Surgery | March 29, 2016 | Volume: 155 | Issue: 1 | Pages: 87-93

10.1177/0194599816639932 | PMID 27026738 Get It

ObjectiveDemonstrate the need for increased education regarding otolaryngology‐related manifestations of human papillomavirus (HPV). Highlight a need to incorporate otolaryngology‐related manifestations of HPV in vaccine counseling.Study DesignSurvey.SettingTertiary care academic children’s hospital.SubjectsPediatric residents, fellows, and staff.MethodsAn online survey was made available regarding HPV education and vaccination.ResultsParticipants (N = 348) initiated the survey representing 28.4%, 25.6%, and 19.0% postgraduate year 1, 2, and 3 residents, respectively, as well as 17.5% chief residents/fellows and 9.5% attendings. Participants rated their prior education as none or fair regarding recurrent respiratory papillomatosis (63.8%) and oropharyngeal squamous cell carcinoma (68.3%). In contrast, 60.6% and 70.9% rated their education on genital warts and cervical cancer correspondingly as good or excellent. When asked what was routinely discussed during HPV vaccine counseling, 63.3% reported “never” discussing recurrent respiratory papillomatosis and 52.9% “never” discussing oropharyngeal squamous cell carcinoma. A range from 92.7% to 95.5% responded that there was a need for increased education regarding HPV and its role in recurrent respiratory papillomatosis and oropharyngeal squamous cell carcinoma.ConclusionsIncreased education about HPV and its otolaryngology‐related manifestations should be undertaken to increase provider, patient, and parent awareness of recurrent respiratory papillomatosis and oropharyngeal squamous cell carcinoma. We propose that discussing the risks of otolaryngology‐related disease be routinely included in HPV vaccination counseling.
Mayo Clinic Zebrafish Facility Overview
Leveque, Ryan E., Clark, Karl J. , Ekker, Stephen C. , Ekker, Stephen C , Clark, Karl J

Zebrafish | March 29, 2016 | Volume: 13 | Issue: 1_suppl | Pages: No page available

10.1089/zeb.2015.1227 | PMID 27023741 Get It

Abstract The zebrafish ( Danio rerio ) is a premier nonmammalian vertebrate model organism. This small aquatic fish is utilized in multiple disciplines in the Mayo Clinic community and by many laboratories around the world because of its biological similarity to humans, its advanced molecular genetics, the elucidation of its genome sequence, and the ever-expanding and outstanding new biological tools now available to the zebrafish researcher. The Mayo Clinic Zebrafish Facility (MCZF) houses ∼2,000 tanks annotated using an in-house, Internet cloud-based bar-coding system tied to our established zfishbook.org web infrastructure. Paramecia are the primary food source for larval fish rearing, using a simplified culture protocol described herein. The MCZF supports the specific ongoing research in a variety of laboratories, while also serving as a local hub for new scientists as they learn to tap into the potential of this model system for understanding normal development, disease, and as models of health.
Molecular classification of cancer with the 92-gene assay in cytology and limited tissue samples
Brachtel, Elena F. , Operaña, Theresa N., Sullivan, Peggy , Kerr, Sarah E. , Cherkis, Karen, Schroeder, Brock E. , Schnabel, Catherine A. , Dry, Sarah

Oncotarget | March 29, 2016 | Volume: 7 | Issue: 19 | Pages: 27220-27231

10.18632/oncotarget.8449 | PMID 27034010 Get It

Implementation of Clinical Decision Support Rules to Reduce Repeat Measurement of Serum Ionized Calcium, Serum Magnesium, and N-Terminal Pro-B-Type Natriuretic Peptide in Intensive Care Unit Inpatients
Moyer, Ann M. , Saenger, Amy K., Baumann, N, Block, Darci R , Botz, Chad M. , Jaffe, Allan S. , Hanson, Curtis A. , Karon, Brad S. , Willrich, Maria, Donato, Leslie J. , Baumann, Nikola A, Khan, Munawwar A., Willrich, Maria Alice V. , Khan, Munawwar Ali , Jaffe, Allan S.

Clinical Chemistry | March 28, 2016 | Volume: 62 | Issue: 6 | Pages: 824-830

10.1373/clinchem.2015.250514 | PMID 27022069 Get It

Abstract BACKGROUND We assessed the impact of clinical decision support (CDS) rules within the electronic health record for ionized calcium (iCa), serum magnesium (Mg), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in intensive care unit (ICU) inpatients at a large academic center. METHODS A repeat order for measurement of iCa or Mg placed within 24 (iCa) or 48 (Mg) h of a previously nonactionable result, or additional orders for NT-proBNP beyond 1 within a single hospitalization, triggered a CDS pop-up alert showing the prior result and offering the opportunity to cancel the order or to place the order after entering an indication for repeat testing. The number of tests performed for each of these analytes and incidence of adverse clinical outcomes potentially associated with hypocalcemia or hypomagnesemia were compared between the 90-day period before CDS implementation and two 90-day periods immediately following. RESULTS iCa test volumes decreased by 48%, Mg by 39%, and NT-proBNP by 28% in the 90-day period immediately following implementation and remained decreased by 54%, 49%, and 22%, respectively, during the following 90-day period (all P values <0.0002). Adverse clinical outcomes potentially associated with hypocalcemia or hypomagnesemia did not increase (all P-values >0.17). CONCLUSIONS Implementation of CDS dramatically decreased repeat testing of iCa, Mg, and NT-proBNP without adversely impacting clinical outcomes in the ICU. Expansion of the rules from the ICU units to include the entire hospitalized patient population and expansion to additional analytes is expected to lead to further reductions in testing.
Evolving Techniques in Pancreatic Surgery
Radenković, Dejan , Farnell, Michael B., Bassi, Claudio, Besselink, Marc G. , Salvia, Roberto , Besselink, Marc G

Gastroenterology Research and Practice | March 28, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-2

10.1155/2016/4289724 | PMID 27118968 Get It

Vascular Toxicities of Cancer Therapies
Herrmann, Joerg , Yang, Eric H. , Iliescu, Cezar , Charitakis, Konstantinos, Hakeem, Abdul , Toutouzas, Konstantinos , Leesar, Massoud A. , Marmagkiolis, Konstantinos , Iliescu, Cezar A, Cilingiroglu, Mehmet , Grines, Cindy L. , Çilingiroğlu, Mehmet , Yang, Eric

Circulation | March 28, 2016 | Volume: 133 | Issue: 13 | Pages: 1272-1289

10.1161/circulationaha.115.018347 | PMID 27022039 Get It

Since the late 1990s, there has been a steady decline in cancer-related mortality, in part related to the introduction of so-called targeted therapies. Intended to interfere with a specific molecular pathway, these therapies have, paradoxically, led to a number of effects off their intended cancer tissue or molecular targets. The latest examples are tyrosine kinase inhibitors targeting the Philadelphia Chromosome mutation product, which have been associated with progressive atherosclerosis and acute vascular events. In addition, agents designed to interfere with the vascular growth factor signaling pathway have vascular side effects ranging from hypertension to arterial events and cardiomyocyte toxicity. Interestingly, the risk of cardiotoxicity with drugs such as trastuzumab is predicted by preexisting cardiovascular risk factors and disease, posing the question of a vascular component to the pathophysiology. The effect on the coronary circulation has been the leading explanation for the cardiotoxicity of 5-fluorouracil and may be the underlying the mechanism of presentation of apical ballooning syndrome with various chemotherapeutic agents. Classical chemotherapeutic agents such as cisplatin, often used in combination with bleomycin and vinca alkaloids, can lead to vascular events including acute coronary thrombosis and may be associated with an increased long-term cardiovascular risk. This review is intended to provide an update on the evolving spectrum of vascular toxicities with cancer therapeutics, particularly as they pertain to clinical practice, and to the conceptualization of cardiovascular diseases, as well. Vascular toxicity with cancer therapy: the old and the new, an evolving avenue.
A Young Man With Progressive Language Difficulty and Early-Onset Dementia
Botha, Hugo , Jones, Lyell K. , Parisi, Joseph E. , Klaas, James P. , Boeve, Bradley F. , Jones, Lyell K , Botha, Hugo

JAMA Neurology | March 28, 2016 | Volume: 73 | Issue: 5 | Pages: 595

10.1001/jamaneurol.2016.0246 | PMID 27019131 Get It

An MRI‐Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease
Raman, Mekala R., Schwarz, Christopher G. , Murray, Melissa E. , Lowe, Val J. , Jack, Clifford R. , Kantarci, Kejal , Dickson, Dennis W. , Jack, Clifford R , Schwarz, Christopher G , Kantarci, Kejal , Murray, Melissa E

Journal of Neuroimaging | March 28, 2016 | Volume: 26 | Issue: 3 | Pages: 264-268

10.1111/jon.12341 | PMID 27017996 Get It

ABSTRACTBACKGROUND AND PURPOSEPathologic diagnosis is the gold standard in evaluating imaging measures developed as biomarkers for pathologically defined disorders. A brain MRI atlas representing autopsy‐sampled tissue can be used to directly compare imaging and pathology findings. Our objective was to develop a brain MRI atlas representing the cortical regions that are routinely sampled at autopsy for the diagnosis of Alzheimer's disease (AD).METHODSSubjects (n = 22; ages at death = 70‐95) with a range of pathologies and antemortem 3T MRI were included. Histology slides from 8 cortical regions sampled from the left hemisphere at autopsy guided the localization of the atlas regions of interest (ROIs) on each subject's antemortem 3D T1‐weighted MRI. These ROIs were then registered to a common template and combined to form one ROI representing the volume of tissue that was sampled by the pathologists. A subset of the subjects (n = 4; ages at death = 79‐95) had amyloid PET imaging. Density of β‐amyloid immunostain was quantified from the autopsy‐sampled regions in the 4 subjects using a custom‐designed ImageScope algorithm. Median uptake values were calculated in each ROI on the amyloid‐PET images.RESULTSWe found an association between β‐amyloid plaque density in 8 ROIs of the 4 subjects (total ROI n = 32) and median PiB SUVR (r2 = .64; P < .0001).CONCLUSIONSIn an atlas developed for imaging and pathologic correlation studies, we demonstrated that antemortem amyloid burden measured in the atlas ROIs on amyloid PET is strongly correlated with β‐amyloid density measured on histology. This atlas can be used in imaging and pathologic correlation studies.
Targeting childhood, adolescent and young adult non‐Hodgkin lymphoma: therapeutic horizons
Galardy, Paul J. , Hermiston, Michelle L. , Bedekovics, Tibor

British Journal of Haematology | March 28, 2016 | Volume: 173 | Issue: 4 | Pages: 625-636

10.1111/bjh.14016 | PMID 27019108 Get It

SummaryNon‐Hodgkin lymphoma (NHL) is the third most common malignancy in children, adolescents and young adults (CAYA). NHL is a diverse set of diseases that arise at key regulatory checkpoints during B or T cell development in the bone marrow, germinal centre or thymus. While advances in the use of conventional cytotoxic agents have led to dramatic improvements in survival, these cures are associated with significant acute and long‐term toxicities. Moreover, the prognosis for CAYA patients with relapsed or refractory NHL remains dismal, with the vast majority dying of their disease. Thanks to a large number of candidate‐based biological studies, together with large‐scale sequencing efforts, there has been an explosion of knowledge regarding the molecular pathophysiology of B‐ and T‐NHL. This has ushered development of a flurry of novel therapeutic approaches that may simultaneously provide new hope for relapsed patients and an opportunity to reduce the therapeutic burden in newly diagnosed CAYA. Here we review a selection of the most promising new therapeutic approaches to these diseases. While the vast majority of these agents are untested in children, on‐going work from many cooperative groups will soon explore their use in paediatric disease, in hope of further improving outcomes while maximizing quality of life.
Insights into the pathogenic mechanisms of Chromosome 9 open reading frame 72 (C9orf72) repeat expansions
Todd, Tiffany W. , Petrucelli, Leonard

Journal of Neurochemistry | March 26, 2016 | Volume: 138 | Issue: S1 | Pages: 145-162

10.1111/jnc.13623 | PMID 27016280 Get It

AbstractThe identification of a hexanucleotide repeat expansion in a non‐coding region of C9orf72 as a major cause of both frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) drastically changed the field of research on both of these conditions. Yet, despite the vast amount of work aimed at elucidating the molecular mechanisms underlying the role of this repeat in disease, the exact pathomechanisms are still unclear. A reduction in the expression of the C9orf72 gene is observed in patients, but a gain‐of‐function model is now preferred. The hexanucleotide repeat expansion forms RNA foci in the central nervous system (CNS) of repeat‐positive FTD and ALS patients, and these foci are believed to sequester RNA‐binding proteins (RBPs) and impair their function in RNA processing. At the same time, the repeat undergoes repeat‐associated non‐ATG translation to produce dipeptide repeat proteins that also form inclusions in the patient CNS. Studies from cells and flies suggest that these proteins may also be an important factor in the disease. Finally, the hexanucleotide repeat also induces the mislocalization and aggregation of TAR DNA‐binding protein 43 (TDP‐43) through an as yet unknown mechanism. This review covers the different potential pathogenic factors that have been put forth for C9orf72‐repeat‐associated FTD and ALS (C9‐FTD/ALS), while highlighting some remaining questions. image A repeat expansion in C9orf72 is a common cause of both frontal temporal dementia and amyotrophic lateral sclerosis. Although there is a decrease in C9orf72 expression in patients, this repeat is believed to induce disease primarily through an unknown gain‐of‐function mechanism involving the RNA, repeat‐associated non‐AUG translation, or both. This review summarizes and discusses current knowledge on C9orf72 repeat‐associated pathophysiology.This article is part of the Frontotemporal Dementia special issue.